[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 287,957,088
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 14,315 M
  • EBITDA $ 20,048 M
  • 60-Month Beta 0.26
  • Price/Sales 4.89
  • Price/Cash Flow 14.36
  • Price/Book 6.08

Options Overview Details

View History
  • Implied Volatility 30.47% (+1.69%)
  • Historical Volatility 20.31%
  • IV Percentile 90%
  • IV Rank 74.45%
  • IV High 34.22% on 02/05/26
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 19) 8.81 (4.74%)
  • Put/Call Vol Ratio 1.14
  • Today's Volume 823
  • Volume Avg (30-Day) 2,504
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 82,726
  • Open Int (30-Day) 84,874
  • Expected Range 176.86 to 194.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.53
  • Number of Estimates 5
  • High Estimate $2.58
  • Low Estimate $2.49
  • Prior Year $2.18
  • Growth Rate Est. (year over year) +16.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
180.00 +3.15%
on 05/05/26
191.50 -3.04%
on 05/21/26
+0.47 (+0.25%)
since 04/29/26
3-Month
180.00 +3.15%
on 05/05/26
207.30 -10.43%
on 04/10/26
-22.78 (-10.93%)
since 02/27/26
52-Week
137.23 +35.30%
on 07/21/25
212.71 -12.71%
on 02/18/26
+44.91 (+31.91%)
since 05/28/25

Most Recent Stories

More News
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of IMFINZI added to BCG vs. BCG alone

AZN : 185.67 (+0.18%)
AZN.LN : 13,801.998 (+0.48%)
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival...

AZN : 185.67 (+0.18%)
AZN.LN : 13,801.998 (+0.48%)
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI ® (durvalumab) and IMJUDO ® (tremelimumab-actl) in early liver...

AZN : 185.67 (+0.18%)
AZN.LN : 13,801.998 (+0.48%)
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

SSNLF : 140.0000 (unch)
BABA : 124.22 (-1.54%)
AZN : 185.67 (+0.18%)
VXUS : 86.06 (+0.08%)
NVS : 150.17 (-0.81%)
TME : 9.22 (+1.43%)
TSM : 418.45 (-1.51%)
IXUS : 96.74 (+0.05%)
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension ...

AZN : 185.67 (+0.18%)
AZN.LN : 13,801.998 (+0.48%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial...

AZN : 185.67 (+0.18%)
AZN.LN : 13,801.998 (+0.48%)
Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.

The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.

NVDA : 211.14 (-1.45%)
AZN : 185.67 (+0.18%)
AMD : 516.10 (-0.38%)
ARM : 353.29 (+5.37%)
GSK : 50.54 (-1.37%)
TSM : 418.45 (-1.51%)
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

Perioperative IMFINZI plus IMJUDO® (tremelimumab-actl) and neoadjuvant EV showed a statistically significant and clinically meaningful improvement in event-free survival and a favorable trend for overall...

AZN : 185.67 (+0.18%)
AZN.LN : 13,801.998 (+0.48%)
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech

Analysts have initiated bullish coverage of Aprea Therapeutics with price targets up to 6x current levels, citing the superior safety profile and $700M peak sales potential of its WEE1 inhibitor program...

AZN : 185.67 (+0.18%)
ZNTL : 4.00 (-1.23%)
ACRV : 1.6000 (-1.84%)
SDGR : 15.20 (+7.34%)
APRE : 0.8926 (-4.07%)
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

AZN : 185.67 (+0.18%)
ABBV : 217.72 (-0.42%)
GSK : 50.54 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 189.41
2nd Resistance Point 188.26
1st Resistance Point 186.96
Last Price 185.67
1st Support Level 184.51
2nd Support Level 183.36
3rd Support Level 182.06

See More

52-Week High 212.71
Last Price 185.67
Fibonacci 61.8% 183.88
Fibonacci 50% 174.97
Fibonacci 38.2% 166.06
52-Week Low 137.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.